Giuseppe Caruso, Gynecology Oncology Specialist at European Institute of Oncology, shared a post a post on LinkedIn:
“Are PARP inhibitors always the right first move in OC?
No question for BRCAm and HRD-positive OCs. But by now we’ve learned that they are not a ‘one-size-fits-all’ strategy.
Early PARPi use definitely improves first PFS, yet may be associated with shorter intervals to later recurrences, raising concerns about downstream treatment efficacy.
For HRD-negative patients, we should pause and weight the potential long-term impact.
This figure from a Society of Gynecologic Oncology 2026 Winter Meeting abstract tells an insightful story: early gain, possible later cost.”
More posts featuring Giuseppe Caruso.